{"id":238368,"date":"2026-06-28T16:17:00","date_gmt":"2026-06-28T20:17:00","guid":{"rendered":"https:\/\/testing.news-you-need.com\/index.php\/2026\/06\/28\/insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration\/"},"modified":"2026-06-28T17:15:10","modified_gmt":"2026-06-28T21:15:10","slug":"insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration","status":"publish","type":"post","link":"https:\/\/testing.news-you-need.com\/index.php\/2026\/06\/28\/insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration\/","title":{"rendered":"Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration"},"content":{"rendered":"<p><a href=\"https:\/\/www.genengnews.com\/topics\/artificial-intelligence\/insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration\/\">Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration<\/a><\/p>\n<p><a href=\"https:\/\/www.genengnews.com\/topics\/artificial-intelligence\/insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration\/\">https:\/\/www.genengnews.com\/topics\/artificial-intelligence\/insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-06-28 16:17:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.genengnews.com\">www.genengnews.com<\/a><\/p>\n<ul>\n<li>Insilico Medicine has partnered with SK Biopharmaceuticals to use its AI-based Pharma.AI platform for discovering new drug candidates targeting disorders in the neuroimmune area of the central nervous system (CNS), potentially generating up to $2.5 billion for Insilico.<\/li>\n<li>The collaboration will leverage Insilico&#8217;s strengths in target validation, generative chemistry, and molecule optimization, with SK providing its expertise in development and clinical capabilities for neuroimmune disorders.<\/li>\n<li>SK Biopharmaceuticals plans to drive the late-stage development and commercialization of these new therapies.<\/li>\n<li>Insilico Medicine, known for its focus on longevity-related targets, is also advancing a pipeline of over 40 programs across various indications, including cancer and neurodegenerative diseases.<\/li>\n<li>Notably, Insilico is undergoing clinical studies for rentosertib, a drug targeting idiopathic pulmonary fibrosis (IPF), which has shown promising early results.<\/li>\n<li>This partnership signifies a significant milestone for Insilico, as it marks its second multi-billion-dollar collaboration in 2024, following a similar agreement with Eli Lilly.<\/li>\n<li>Alex Zhavoronkov, Insilico&#8217;s CEO and co-founder, emphasized that the company is leveraging its cutting-edge AI technology to transition from an experimental tool to a practical drug discovery method, highlighting their focus on using AI to identify and develop new drugs efficiently.<\/li>\n<\/ul>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration https:\/\/www.genengnews.com\/topics\/artificial-intelligence\/insilico-sk-launch-up-to-2-5b-neuroimmune-ai-drug-collaboration\/ Publish Date: 2026-06-28 16:17:00 Source Domain:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":238369,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/06\/Alex_in_Lab-3.jpg","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-238368","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence"],"_links":{"self":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/238368"}],"collection":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=238368"}],"version-history":[{"count":1,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/238368\/revisions"}],"predecessor-version":[{"id":238370,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/238368\/revisions\/238370"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/238369"}],"wp:attachment":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=238368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=238368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=238368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}